Report of Foreign Issuer (6-k)

FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION


Washington D.C. 20549

 

 

Report of Foreign Issuer

 

 

Pursuant to Rule 13a-16 or 15d-16 of


the Securities Exchange Act of 1934

 

 

 

For period ending July 2015

 

GlaxoSmithKline plc

(Name of registrant)


 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)


 

 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F


 

 

Form 20-F x     Form 40-F


 

--


 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.


 

 

Yes      No x

--

                                                                                                           GlaxoSmithKline plc

 

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 10 July 2015 that the following Directors and Persons Discharging Managerial Responsibilities acquired GSK Ordinary Shares ('Shares') on 9 July 2015, at a price of 1368.97 pence per Ordinary Share, through GSK's ShareReward Plan (the 'Plan'):

 

 

Director/PDMR	Number of Shares under the personal contribution element of the Plan	Number of Shares under the matching element of the Plan (GSK contribution)
Sir Andrew Witty	9	9
Mr R G Connor	9	9
Mr S Dingemans	9	9
Mr N Hirons	10	10
Mr D S Redfern	9	9
Ms C Thomas	9	9
Mr P C Thomson	9	9
Dr P J T Vallance	9	9
Ms E Walmsley	9	9
Mrs V A Whyte	9	9

V A Whyte

Company Secretary

 

10 July 2015

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.


 

 

GlaxoSmithKline plc

(Registrant)


Date: July 10, 2015 

 

 

By: VICTORIA WHYTE

----------------------

 

 

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc